Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Thermo Fisher Scientific cut the ribbon to open a highly automated manufacturing plant in North Carolina—featuring a ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultra rare disease candidate, providing a ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Masimo is taking the U.S. government to court over its decision to allow blood oxygen tracking to return to the Apple Watch.

The FDA’s rebuff of Replimune’s melanoma candidate has sent waves through the industry, prompting Krystal Biotech to shutter a clinical trial.